Subcutaneous Dosing for 5-Amino-1MQ
Critical Assessment
There is no established evidence supporting the safety or efficacy of subcutaneous 5-amino-1MQ (5-AMQ) for any medical indication, and this compound should not be used in clinical practice.
The provided evidence contains no guidelines, FDA drug labels, or high-quality clinical trials addressing subcutaneous administration of 5-amino-1MQ in humans. The available research is limited to:
Available Evidence Analysis
Pharmacokinetic Data Only
- A single rat study demonstrated that 5-AMQ achieved plasma concentrations of 2252 ng/mL after oral administration, with 38.4% oral bioavailability and a terminal half-life of 6.90 hours 1
- This preclinical study examined intravenous and oral routes only—subcutaneous administration was not evaluated 1
- The compound functions as a Nicotinamide N-methyltransferase (NNMT) inhibitor, theoretically relevant to metabolic conditions, but no human efficacy or safety data exist 1
Critical Knowledge Gaps
- No human clinical trials have been published evaluating 5-AMQ by any route of administration
- No established dosing regimens exist for subcutaneous, oral, or any other route in humans
- No safety profile has been characterized in human subjects
- No regulatory approval exists from the FDA or any international regulatory body
Evidence Misidentification
The provided guidelines discuss entirely different compounds:
- 5-aminosalicylic acid (5-ASA/mesalamine) for inflammatory bowel disease 2, 3, 4
- 5-aminolevulinic acid (ALA) for photodynamic therapy in dermatology 2, 5, 6
- 5-fluorouracil (5-FU) for topical cancer treatment 2, 5
These are pharmacologically distinct molecules with completely different mechanisms, indications, and safety profiles from 5-amino-1-methylquinolinium (5-AMQ).
Clinical Recommendation
Do not administer 5-amino-1MQ by subcutaneous injection or any other route outside of properly designed clinical trials with institutional review board approval and informed consent. The absence of human safety data, established dosing parameters, and regulatory oversight makes any clinical use inappropriate and potentially dangerous.